Frances C Hall

Summary

Affiliation: University of Cambridge
Country: UK

Publications

  1. pmc The TRACTISS protocol: a randomised double blind placebo controlled clinical trial of anti-B-cell therapy in patients with primary Sjögren's Syndrome
    Sarah Brown
    Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds LS2 9JT, UK
    BMC Musculoskelet Disord 15:21. 2014
  2. ncbi request reprint Local activation and systemic dysregulation of T lymphocytes in Sjögren's syndrome
    Robert Busch
    Division of Rheumatology, Department of Medicine, University of Cambridge, Cambridge, UK
    Curr Pharm Biotechnol 13:2009-21. 2012
  3. pmc Put your heart into the joint benefits of statins!
    Frances C Hall
    ARC Rheumatology Lecturer, Addenbrooke s Hospital, Cambridge, UK
    Arthritis Res Ther 5:202-4. 2003
  4. pmc Cold hands--strained heart? Advances in the management of Raynaud's phenomenon and pulmonary hypertension
    Frances C Hall
    University of Cambridge School of Clinical Medicine, Addenbrooke s Hospital, Cambridge, UK
    Arthritis Res Ther 7:126-8. 2005
  5. ncbi request reprint Disease modification and cardiovascular risk reduction: two sides of the same coin?
    F C Hall
    University of Cambridge School of Medicine, UK
    Rheumatology (Oxford) 44:1473-82. 2005
  6. ncbi request reprint Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis
    Kaisa M Maki-Petaja
    Clinical Pharmacology Unit, University of Cambridge, Cambridge, United Kingdom
    J Am Coll Cardiol 50:852-8. 2007
  7. ncbi request reprint Inducible nitric oxide synthase activity is increased in patients with rheumatoid arthritis and contributes to endothelial dysfunction
    Kaisa M Maki-Petaja
    Clinical Pharmacology Unit, University of Cambridge, Addenbrooke s Hospital, Box 110, Cambridge, UK
    Int J Cardiol 129:399-405. 2008
  8. ncbi request reprint Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy
    Kaisa M Maki-Petaja
    Clinical Pharmacology Unit, University of Cambridge, Addenbrooke s Hospital, Box 110, Cambridge CB2 2QQ, United Kingdom
    Circulation 114:1185-92. 2006
  9. ncbi request reprint Targeting CVD risk in chronic connective tissue disease
    Anshuman P Malaviya
    Rheumatology Clinical Research Unit, Addenbrooke s Hospital, Cambridge
    Practitioner 256:21-6, 3. 2012

Collaborators

  • Carmel M McEniery
  • Anthony D Booth
  • N Dalbeth
  • - Yasmin
  • Joseph Cheriyan
  • I B Wilkinson
  • Kaisa M Maki-Petaja
  • Robert Busch
  • John Brown
  • Sharon M L Wallace
  • Sarah Brown
  • Anshuman P Malaviya
  • Costantino Pitzalis
  • Colin Pease
  • Ng Wan-Fai
  • Paul Emery
  • Ana Poveda-Gallego
  • Nurhan Sutcliffe
  • Sharon Ruddock
  • Saaeha Rauz
  • Simon Bowman
  • Iain Macleod
  • Pete Smith
  • Claire Hulme
  • Michele Bombardieri
  • Catherine Reynolds
  • Janine Gray
  • Nuria Navarro Coy
  • Colin Everett
  • Luke Dawson
  • Sue Pavitt
  • Clodagh Woods
  • Emma Skinner
  • John Rout
  • Elizabeth Price
  • Andreas V Hadjinicolaou
  • Mike J Ashby
  • Philip W P Bearcroft
  • Srinivasan Harish
  • Anita Furlong

Detail Information

Publications9

  1. pmc The TRACTISS protocol: a randomised double blind placebo controlled clinical trial of anti-B-cell therapy in patients with primary Sjögren's Syndrome
    Sarah Brown
    Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds LS2 9JT, UK
    BMC Musculoskelet Disord 15:21. 2014
    ..For patients with PSS there is currently no effective therapy that can alter the progression of the disease. The aim of the TRACTISS study is to establish whether in patients with PSS, treatment with rituximab improves clinical outcomes...
  2. ncbi request reprint Local activation and systemic dysregulation of T lymphocytes in Sjögren's syndrome
    Robert Busch
    Division of Rheumatology, Department of Medicine, University of Cambridge, Cambridge, UK
    Curr Pharm Biotechnol 13:2009-21. 2012
    ..A better understanding of T-cell dysregulation in PSS is required in order to understand its contribution to disease, aid prognosis, and improve therapeutic interventions aimed at this aspect of the disease...
  3. pmc Put your heart into the joint benefits of statins!
    Frances C Hall
    ARC Rheumatology Lecturer, Addenbrooke s Hospital, Cambridge, UK
    Arthritis Res Ther 5:202-4. 2003
  4. pmc Cold hands--strained heart? Advances in the management of Raynaud's phenomenon and pulmonary hypertension
    Frances C Hall
    University of Cambridge School of Clinical Medicine, Addenbrooke s Hospital, Cambridge, UK
    Arthritis Res Ther 7:126-8. 2005
  5. ncbi request reprint Disease modification and cardiovascular risk reduction: two sides of the same coin?
    F C Hall
    University of Cambridge School of Medicine, UK
    Rheumatology (Oxford) 44:1473-82. 2005
    ..Long-term studies of such interventions are needed to further clarify the benefits of intensive cardiovascular risk management in these patients...
  6. ncbi request reprint Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis
    Kaisa M Maki-Petaja
    Clinical Pharmacology Unit, University of Cambridge, Cambridge, United Kingdom
    J Am Coll Cardiol 50:852-8. 2007
    ..The aim of this study was to investigate the effect of simvastatin and ezetimibe on inflammation, disease activity, endothelial dysfunction, and arterial stiffness in a cohort of rheumatoid arthritis (RA) patients...
  7. ncbi request reprint Inducible nitric oxide synthase activity is increased in patients with rheumatoid arthritis and contributes to endothelial dysfunction
    Kaisa M Maki-Petaja
    Clinical Pharmacology Unit, University of Cambridge, Addenbrooke s Hospital, Box 110, Cambridge, UK
    Int J Cardiol 129:399-405. 2008
    ..The aim of the study was to establish the contribution of iNOS to endothelial function...
  8. ncbi request reprint Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy
    Kaisa M Maki-Petaja
    Clinical Pharmacology Unit, University of Cambridge, Addenbrooke s Hospital, Box 110, Cambridge CB2 2QQ, United Kingdom
    Circulation 114:1185-92. 2006
    ..In addition, we tested the hypothesis that aortic stiffness could be reduced with anti-tumor necrosis factor-alpha (TNF-alpha) therapy...
  9. ncbi request reprint Targeting CVD risk in chronic connective tissue disease
    Anshuman P Malaviya
    Rheumatology Clinical Research Unit, Addenbrooke s Hospital, Cambridge
    Practitioner 256:21-6, 3. 2012
    ..Atherogenesis in the context of autoimmune disease results from a complex interplay between traditional risk factors, disease-specific factors and drug-related adverse effects. Chronic inflammation itself modifies the lipid profile...